Skip to content

Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilla

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02986594
Enrollment
600
Registered
2016-12-08
Start date
2016-11-30
Completion date
2019-10-31
Last updated
2016-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombophilia With Recurrent Pregnancy Loss

Brief summary

In this clinical cohort study, the investigators observe the efficacy of low molecular weight heparin in the treatment of thrombophilia with recurrent pregnancy loss with a prospective randomized controlled trial.

Interventions

DRUGAspirin
DRUGHeparin

Sponsors

Shanghai First Maternity and Infant Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Woman who had their Second miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss. Signed consent form.

Exclusion criteria

1. having experiencedsevere allergies, trauma history and/or operation history within 3 months 2. with a history of mental illness and/or family history of mental illness 3. limb disabled 4. taking medicine within one month 5. suffering major events or having mood swings 6. with a history of recurrent pregnancy loss 7. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine rotine) 8. Chromosome aberrations in anyone of the couple. 9. patients who have drug contraindications

Design outcomes

Primary

MeasureTime frame
D-Dimerthrough study completion, an average of 3 year

Secondary

MeasureTime frame
BMI in kg/m^2through study completion, an average of 3 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026